齐拉西酮治疗伴发抑郁症状精神分裂的临床研究

Clinical study of ziprasidone in the treatment of schizophrenia with depressive symptoms

目的观察研究齐拉西酮治疗伴发抑郁症状精神分裂的临床效果,总结其临床应用价值。方法选取本院2009年6月～2011年6月84例伴发抑郁症状精神分裂的患者,随机分为观察组和对照组,各42例,观察组使用齐拉西酮治疗,对照组使用利培酮治疗,观察比较两组的治疗效果。结果两组患者治疗前后的PANSS、HAMD、HAMA评分比例比较差异有统计学意义(P<0.05),观察组改善程度更为显著,差异具有统计学意义(P<0.05)。结论齐拉西酮对伴发抑郁症状精神分裂的临床效果显著,优于使用利培酮治疗,能够有效缓解抑郁焦虑症状,起效迅速,安全性高,值得在临床上合理推广。

Objective To observe the clinical effects of ziprasidone in the treatment of schizophrenia with depressive symptoms, and summarize its clinical application value. Methods Eighty-four cases of schizophrenic patients with depressive symptoms in our hospital from June 2009 to June 2011 were selected, and randomly divided into the observation group and the control group, each group had 42 cases. The observation group was given ziprasidone treatment, the control group was given risperidone treatment. The therapeutic effect between the two groups was compared. Results There were significant differences in the PANSS, HAMD and HAMA scores proportion between the two groups before and after treatment （P 0.05）, and the improvement degree of the observation group was more significantly, with statistically significant difference （P 0.05）. Conclusion The clinical effect of ziprasidone in the treatment of schizophrenia with depressive symptoms is significant, and is better than the risperidone therapy, which can effectively alleviate depression symptoms, has rapid effect and high safety. It is worthy of clinical promotion.